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Background-—The CASTLE-AF (Catheter Ablation versus Standard Conventional Therapy in Patients With Left Ventricular
Dysfunction and Atrial Fibrillation) trial recently reported that catheter ablation of atrial ﬁbrillation (AF) improves survival in heart
failure (HF) with reduced ejection fraction (HFrEF). However, established AF was not associated with mortality in trials of
contemporary HFrEF pharmacotherapies. We investigated whether HFrEF pathogenesis may inﬂuence the conclusions of studies
evaluating the prognostic impact of AF.
Methods and Results-—Using a prospective cohort study of 791 patients with HFrEF, with AF determined using 24-hour
ambulatory ECG monitoring, univariable and multivariable Cox regression analyses were used to deﬁne the association between AF
and mode-speciﬁc mortality (mean follow-up of 5.4 years). One-year HF-related hospitalization was assessed with binary logistic
regression analysis. One-year cardiac remodeling was assessed in a subgroup (n=378) using echocardiography. AF was present in
28.2% of patients, with 9.4% of these being paroxysmal. While AF was associated with increased risk of all-cause mortality (hazard
ratio, 1.27; 95% conﬁdence interval 1.03–1.57), with diverging survival curves after 1 year of follow-up, this association was lost in
age-sex–adjusted analyses. However, AF was associated with increased risk of age-sex–adjusted all-cause mortality in people with
ischemic pathogenesis, with a statistically signiﬁcant interaction between pathogenesis and AF. This was predominantly attributed
to progressive HF deaths. After 1 year, HF hospitalization and cardiac remodeling were not associated with AF, even in people with
ischemic pathogenesis.
Conclusions-—AF is associated with increased risk of death in HFrEF of ischemic pathogenesis, predominantly due to progressive
HF deaths during long-term follow-up. HFrEF pathogenesis should be considered in trial design and interpretation. ( J Am Heart
Assoc. 2018;7:e009770. DOI: 10.1161/JAHA.118.009770.)
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A trial ﬁbrillation (AF) is the most common arrhythmiaencountered in patients with chronic heart failure (HF),1
and its prevalence increases as symptoms progress,
approaching 50% in patients with New York Heart Association
class IV dyspnea.2 The literature describing the association of
AF with adverse outcomes in people with HF and reduced
ejection fraction (HFrEF) is conﬂicting, with only some studies
identifying AF as an independent risk factor for mortality and
morbidity.2,3 Other studies have reported that when analyses
are adjusted for common confounding factors, such as
demographics, AF is no longer an independent predictor of
death.4,5 A meta-analysis including studies from 1996 to
2008 found that, after adjustment for confounding factors, AF
was associated with increased all-cause mortality.6 This
analysis largely included participants of randomized controlled
trials of treatments that are now considered standard in the
management of HFrEF, and device therapy was not routine.
More contemporary data from a post hoc analysis of the
PARADIGM-HF (Prospective Comparison of ARNI With ACEI to
Determine Impact on Global Mortality and Morbidity in Heart
Failure) and ATMOSPHERE (Aliskiren Trial to Minimize
Outcomes in Patients With Heart Failure) trials found that
paroxysmal AF (pAF), but not persistent/permanent AF, was
associated with increased composite risk of cardiovascular
death or HF hospitalization. Neither pAF nor persistent/
permanent AF was associated with increased all-cause
mortality, and no subgroup analyses of ischemic pathogenesis
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were conducted.7 Some reports suggest that AF is associated
with increased mortality in patients with ischemic HF, but
include patients with HF and preserved ejection fraction
(HFpEF) and apply outdated therapeutic strategies.8,9 It is
therefore unclear whether there is an adverse interaction
between AF and ischemic pathogenesis in patients receiving
contemporary HFpEF management.
Against the backdrop of these conﬂicting data, interven-
tional therapies for AF are increasingly applied in people with
HFrEF, following reports of improvements in left ventricular
(LV) ejection fraction and functional capacity.10 Moreover,
recently published data have suggested a reduction in
mortality and HF hospitalization with the use of catheter
ablation for paroxysmal or persistent AF in the setting of
HFrEF.11 However, the discrepancy with the described
analysis of the PARADIGM-HF and ATMOSPHERE trials7
emphasizes the need to understand which patients with
HFrEF experience an increased risk of adverse events
associated with AF, in order to guide clinical practice and
research. We have explored the association between AF and
mode-speciﬁc mortality, hospitalization, and cardiac remod-
eling in a prospectively recruited HFrEF cohort, particularly
focusing on the interaction between AF and ischemic
pathogenesis.
Methods
The data, analytic methods, and study materials will not be
made available to other researchers for purposes of repro-
ducing the results or replicating the procedure since the
complete study data set contains potentially identifying data;
however, data will be made available by the corresponding
author to other researchers who have appropriate ethical
approval and data protection arrangements.
We conducted a prospective multicenter cohort study of
1091 patients, aiming to deﬁne risk factors for adverse
outcomes in people with HFrEF receiving contemporary
evidence-based care.12 All patients were adults (age ≥18 years)
with stable signs and symptoms of chronic HF for at least
3 months, had LV ejection fraction ≤45% on 2-dimensional
transthoracic echocardiography, and were recruited between
June 2006 and December 2011. Leeds West Research
Ethics Committee provided ethical approval, and all recruits
provided written informed consent, in accordance with the
Declaration of Helsinki. This analysis is restricted to the 791
patients with complete ambulatory 24-hour ECG data to
ensure systematic assessment of cardiac rhythm.12
As previously described,12 details of medical history and
drug history were collected at recruitment. Symptomatic
status was deﬁned using New York Heart Association
classiﬁcation. Transthoracic echocardiography was per-
formed according to British Society of Echocardiography
recommendations.13 Venous blood was collected for mea-
surement of electrolyte concentrations, assessment of renal
function, and hematological parameters, which were per-
formed in the local hospital chemical pathology laboratories.
Estimated glomerular ﬁltration rate was calculated using the
Modiﬁcation of Diet in Renal Disease method.14 Resting heart
rate was measured using 12-lead ECG. Use and dosing of
diuretic therapy, angiotensin-converting enzyme inhibitors,
angiotensin receptor blockers, and b-blockers were collected
at study recruitment. The prescribed daily doses of b-blockers
were expressed relative to the maximal licensed dose of
bisoprolol and diuretic dose was normalized to furosemide.15
Receipt of cardiac resynchronization therapy or implantable
cardioverter-deﬁbrillator (ICD) was deﬁned 6 months after
recruitment to account for device implantation shortly after
referral to the service. In a subset of 408 patients, clinical
review was repeated 1 year later to document changes in
symptomatic status and LV dimensions (remodeling). This
subset represents all patients within the ﬁrst cohort of 628
participants who were alive and willing to attend a study
follow-up visit, as previously described,16 of whom 378 had
24-hour ambulatory ECG data, so were included in this
analysis.
Assessment of AF
During normal, unrestricted, out-of-hospital activity, 24-hour
ambulatory 3-lead ECGs (Lifecard CF, Spacelabs Healthcare)
were obtained. Patients with atrial ﬂutter were included in the
AF group, given the frequent co-occurrence of these rhythms.
Clinical Perspective
What Is New?
• Overall, atrial ﬁbrillation (AF) is not associated with age-sex–
adjusted all-cause or mode-speciﬁc mortality in patients
with heart failure and a reduced ejection fraction (HFrEF)
receiving contemporary therapy.
• However, AF outcomes signiﬁcantly interact with HFrEF
pathogenesis, such that only patients with AF and ischemic
HFrEF experience increased risk of death.
• AF is not associated with risk of heart failure hospitalization
or cardiac remodeling after 1 year of follow-up, even in
ischemic HFrEF.
What Are the Clinical Implications?
• Clinical trials of AF therapies in HFrEF should focus on
patients with ischemic pathogenesis and have long-term
follow-up, to attempt to address this question of how the
increased mortality in this subgroup of patients with HF
could be reduced.
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Patients with AF that was not sustained throughout monitor-
ing were labelled as having pAF. Since monitoring lasted for
24 hours, no further classiﬁcation of persistent or permanent
AF was made. Maximum and minimum ambulatory heart rate
was recorded as described.12
Mortality and Hospitalization Assessment
All patients were registered with the UK Ofﬁce of Population
Censuses and Surveys, which provided details of death.
Censorship took place on May 8, 2016. Classiﬁcation criteria
for the mode of death were deﬁned before the study
commenced, based on previous publications.17 At least 2
senior physicians reviewed each death certiﬁcate and gath-
ered data as required from autopsy reports, hospital notes,
and primary care records. Mode of death was classiﬁed as:
(1) sudden cardiac, if it occurred within 1 hour of a change in
symptoms or during sleep or while the patient was unob-
served (deﬁbrillator therapies were not included as a proxy);
(2) progressive HF, if death occurred after a documented
period of symptomatic or hemodynamic deterioration;
(3) other cardiovascular death, if not occurring suddenly or
in association with progression of HF (eg, cerebrovascular
accident); (4) noncardiovascular death; and (5) unclassiﬁable,
where insufﬁcient information was available to reach a ﬁrm
conclusion. HF-related hospitalization was assessed as
described,12 using institutional clinical event databases
detailing all admissions in recruiting centers. Details of all
nonelective hospitalizations were also collected. Events were
assessed during the ﬁrst year of recruitment and analyzed as
a binary outcome.
Statistical Analysis
All analyses were conducted with SPSS version 23 (IBM).
Continuous data are displayed as means (SEM), and categor-
ical data are displayed as percentages (number). Normality of
distribution was conﬁrmed on skewness testing. Continuous
data were compared with unpaired or paired Student t tests,
as appropriate, and categorical data with v2 tests. Cox
proportional hazards regression was used in univariate and
multivariate mortality analyses, and binary logistic regression
analysis was used for hospitalization analyses. Assessment of
partial residuals was used to conﬁrm no deviation from the
assumption of proportional hazards. Statistical signiﬁcance
was deﬁned as P<0.05.
Results
Of the 791 patients included in this study, AF was present
during ambulatory ECG monitoring in 223 (28.2%), and this
was paroxysmal in 21 (9.4%) of those; baseline characteristics
of patients with and without any AF are presented in Table 1.
Patients with AF were older and less likely to have HF due to
ischemic pathogenesis but had similar LV ejection fraction
and showed only a trend toward worse symptoms assessed
by New York Heart Association class. Patients with AF had a
higher resting heart rate on 12-lead ECG, along with higher
minimum and maximum ambulatory heart rates. The only
signiﬁcant differences in HF pharmacotherapy were higher
diuretic doses and greater digoxin use in patients with AF,
while anticoagulation was also more commonly prescribed to
those with AF. There were similar rates of cardiac resynchro-
nization therapy implantation in each group, but patients with
AF were less likely to have an ICD. Lower rates of ICD
implantation in patients with AF may be related to their
greater age and comorbidity.
Total and Mode-Speciﬁc Mortality
After a mean follow-up period of 5.4 years, 407 deaths had
occurred, of which 232 were cardiovascular (including 127
progressive HF deaths and 59 sudden deaths) and 175 were
noncardiovascular. The presence of AF was associated with
increased risk of all-cause mortality (1.27; 95% conﬁdence
interval, 1.03–1.57 [P<0.05]), primarily driven by an increase
in progressive HF death (1.49; 95% conﬁdence interval, 1.03–
2.15 [P<0.05]) (Figure 1). However, these associations were
lost in age-sex–adjusted analyses (Table 2), suggesting that
the older age and male preponderance of patients with AF
may account for much of their increased risk of death in
unadjusted analyses. If differences in the treatment of
patients with AF (ICD provision, diuretic dose, warfarin use,
and digoxin use) were also included in age-sex–adjusted
analyses, the neutral association of AF with mortality was
unchanged (Table 2). Similarly, if resting heart rate was added
to age-sex–adjusted analyses, the neutral association of AF
with mortality was unchanged (Table 2). However, when
differences in the comorbidity of patients with AF (ischemic
pathogenesis, hemoglobin, and estimated glomerular ﬁltration
rate) were included in age-sex–adjusted analyses, the detri-
mental association of AF with cardiovascular and progressive
HF death returned (Table 2).
In view of the signiﬁcant association of AF with cardio-
vascular death in our age-sex– and comorbidity-adjusted
analyses, and published data linking AF with adverse
outcomes in ischemic heart disease (IHD), we assessed
age-sex–adjusted mortality in subgroups with ischemic and
nonischemic HF. AF was associated with increased risk of all-
cause mortality in people with ischemic pathogenesis, but not
in those with nonischemic pathogenesis, with a statistically
signiﬁcant age-sex–adjusted interaction between pathogene-
sis and AF (Figure 2). Sensitivity analyses excluding patients
with pAF, or those prescribed amiodarone, revealed no
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change in this interaction between AF and ischemic patho-
genesis (P=0.005 and P=0.017, respectively), suggesting that
these factors are unlikely in isolation to explain this
phenomenon. Further exploration of mode-speciﬁc mortality
revealed a similar pattern for cardiovascular, progressive HF,
and sudden death, although no signiﬁcant interaction was
present in any of these analyses. However, the risk of
noncardiovascular death was signiﬁcantly reduced in people
with nonischemic (but not ischemic) HF with a signiﬁcant
interaction between pathogenesis and AF. In order to explore
these observations further, we deﬁned patient characteristics
according to the presence or absence of AF in subgroups with
ischemic and nonischemic pathogenesis (Table 3). This
showed that patients with ischemic HF and AF were
prescribed signiﬁcantly higher doses of loop diuretics and
were more likely to receive a mineralocorticoid receptor
antagonist. This was not the case in people with AF and
nonischemic HF. This is congruent with the higher rates of
progressive HF death in patients with AF in the context of
ischemic HF.
Hospitalization, Cardiac Remodeling, and
Symptomatic Deterioration After 1 Year
After 1 year of follow-up, there were 103 cardiovascular
hospitalizations, of which 46 were caused by worsening HF.
The presence of AF was not associated with the age-sex–
adjusted odds of cardiovascular (0.67; 95% conﬁdence
interval, 0.4–1.11 [P=0.12]) or HF-speciﬁc (0.92; 95% conﬁ-
dence interval, 0.46–1.83; [P=0.81]) hospitalization. In keep-
ing with this, there were also no signiﬁcant differences in
cardiac remodeling, as measured by the change in LV end-
diastolic diameter, LV end-systolic diameter, and LV ejection
fraction after 1 year (Table 4). We also noted no difference in
the prevalence of declining New York Heart Association class
1 year after recruitment. Notably, the observed neutral
association of AF with hospitalization, LV remodeling, and
symptomatic deterioration was unchanged in analyses
restricted to patients with ischemic or nonischemic HF.
Discussion
Our analysis of a large HFrEF cohort with robust baseline
cardiac rhythm assessment and long-term mode-speciﬁc
mortality data provides important new insights into sub-
groups at risk for adverse cardiovascular events associated
with AF. While AF was crudely associated with increased
risk of all-cause and cardiovascular death, simple age-sex
adjustment abrogated these ﬁndings. However, further
analyses revealed a signiﬁcant interaction with ischemic
pathogenesis, such that both all-cause and cardiovascular
death were higher in people with ischemic HF. Notably,
survival curves began to diverge beyond 1 year of follow-up,
potentially explaining our observation that HF hospitalization
and adverse cardiac remodeling were not more likely in
people with AF, even in analyses restricted to ischemic HF.
Our data may offer some explanation for the conﬂicting
literature on the adverse prognostic association of AF and
Table 1. Baseline Patient Characteristics
No AF AF P Value
Age, y 66.5 (0.5) 71.2 (0.7) <0.001
Men 72.4 (411) 77.1 (172) 0.17
Ischemic pathogenesis 66.7 (379) 55.2 (123) 0.002
Diabetes mellitus 25.7 (146) 26 (58) 0.93
COPD 13.7 (78) 13.9 (31) 0.95
PPM/ICD/CRT* 33.3 (189) 28.7 (64) 0.22
ICD 14.8 (84) 5.4 (12) <0.001
CRT 25 (142) 24.2 (54) 0.82
NYHA class 3/4 31.8 (180) 39 (87) 0.054
Warfarin 18.6 (105) 62.6 (139) <0.001
ACEI/ARB 89.2 (504) 85.6 (190) 0.16
b-Blocker 79.8 (451) 77.5 (172) 0.47
MRA 38.6 (218) 45 (100) 0.096
Digoxin 12.9 (73) 44.4 (99) <0.001
Amiodarone 9.9 (56) 7.6 (17) 0.33
Systolic BP, mm Hg 122.3 (0.9) 118.9 (1.4) 0.043
Resting HR on
12-lead ECG, bpm
72.2 (0.8) 78.5 (1.5) <0.001
QRS interval, ms 122.9 (1.3) 119.6 (2.3) 0.2
Hemoglobin, g/dL 13.5 (0.1) 13.9 (0.1) 0.013
Sodium, mmol/L 139.3 (0.1) 139.5 (0.2) 0.43
eGFR, mL/min
per 1.73 m2
55.8 (0.7) 52.8 (1.1) 0.029
LVEF, % 32 (0.4) 32.3 (0.6) 0.71
Minimum
ambulatory HR, bpm
56.5 (0.5) 59.3 (1) 0.009
Maximum
ambulatory HR, bpm
102.6 (0.8) 118.9 (1.8) <0.001
Ramipril
equivalent dose, mg/d
5 (0.2) 4.7 (0.2) 0.17
Bisoprolol
equivalent dose, mg/d
3.4 (0.1) 3.7 (0.2) 0.23
Furosemide equivalent
dose, mg/d
50.5 (2.2) 59.5 (3.4) 0.026
Continuous data are presented as mean (SEM) and compared with Student t tests. ACEI
indicates angiotensin-converting enzyme inhibitor; AF, atrial ﬁbrillation; ARB, angiotensin
receptor blocker; BP, blood pressure; bpm, beats per minute; COPD, chronic obstructive
pulmonary disease; CRT, cardiac resynchronization therapy; eGFR, estimated glomerular
ﬁltration rate; HR, heart rate; ICD, implantable cardioverter-deﬁbrillator; LVEF, left
ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NYHA, New
York Heart Association; PPM, permanent pacemaker.
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suggest that ongoing trials of AF interventions should focus
on populations with ischemic HF and also apply extended
follow-up periods.
AF and Mortality in Populations With HF: Insights
From Conﬂicting Data
A meta-analysis of studies published from 1996 to 2008
reported that AF was associated with increased all-cause
mortality (hazard ratio [HR], 1.4) in those with HF, a ﬁnding
that persisted even after adjustment for confounding
factors.6 However, this analysis included studies with rela-
tively low use of contemporary therapies, such as b-blockers
and angiotensin-converting enzyme inhibitors (prescribed in
24% and 65% of patients, respectively). Furthermore,
mineralocorticoid receptor antagonist and cardiac resynchro-
nization therapy/ICD use was not reported. In contrast, post
hoc analysis of the most contemporary randomized con-
trolled trial data suggested that only pAF was associated with
increased risk of composite cardiovascular death or HF
hospitalization; however, this analysis of the PARADIGM-HF
and ATMOSPHERE trials indicated that AF of any type was
not associated with increased risk of all-cause mortality.7
Again, and in keeping with our own ﬁndings, the HF-ACTION
(Heart Failure: A Controlled Trial Investigating Outcomes of
Exercise Training) study concluded that AF is not an
independent risk factor for increased mortality or hospital-
ization in patients with HFrEF.18 These data markedly
contrast with those of the recently published CASTLE-AF
(Catheter Ablation versus Standard Conventional Therapy in
Patients With Left Ventricular Dysfunction and Atrial Fibril-
lation) trial, which reported a 38% reduction in all-cause
mortality or HF hospitalization in patients receiving catheter
ablation.11 Such remarkable data must be placed in the
Figure 1. Unadjusted all-cause and mode-speciﬁc mortality. Kaplan-Meier curves illustrating (A) all-cause, (B) progressive heart failure,
(C) sudden, and (D) noncardiovascular mortality. AF indicates atrial ﬁbrillation.
DOI: 10.1161/JAHA.118.009770 Journal of the American Heart Association 5
Atrial Fibrillation and Mortality in Ischemic Heart Failure Mercer et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on October 17, 2018
context of the relatively small (and lower-than-planned)
sample of highly selected patients receiving an open-label
intervention. However, the trial does raise important ques-
tions about targeting speciﬁc subgroups at the greatest risk
of adverse events associated with AF. Their inclusion of
patients with pAF is supported by the analysis of the
PARADIGM-HF and ATMOSPHERE trials, yet the subgroup
analysis of the CASTLE-AF trial showed no interaction with
paroxysmal/persistent AF. Our own analysis shows that an
ischemic cause should also be considered a risk factor for
AF-associated mortality, and CASTLE-AF showed a slightly
larger reduction in primary outcome in patients with ischemic
HF (40% versus 26%), although no signiﬁcant interaction was
present. Notably, survival curves only began to diverge after
3 years of follow-up in the CASTLE-AF trial, somewhat
mirroring our own observations.
Table 2. All-Cause and Mode-Speciﬁc Mortality Analyses
Model
Mode of Death
All-Cause Cardiovascular Progressive HF Sudden Noncardiovascular
Unadjusted 1.27 (1.03–1.57)* 1.49 (1.12–1.97)* 1.49 (1.03–2.15)* 1.23 (0.7–2.14) 1.03 (0.73–1.43)
Age-sex 1.04 (0.84–1.28) 1.23 (0.92–1.63) 1.19 (0.83–1.72) 1.16 (0.64–1.96) 0.84 (0.6–1.17)
Age-sex and treatment† 1.03 (0.81–1.320 1.13 (0.81–1.58) 1.04 (0.68–1.59) 1.01 (0.52–1.97) 0.91 (0.62–1.34)
Age-sex and comorbidity‡ 1.23 (0.99–1.54) 1.49 (1.1–2.01)* 1.48 (1–2.2)* 1.37 (0.76–2.49) 1.05 (0.74–1.49)
Age-sex and HR§ 1.04 (0.83–1.32) 1.28 (0.94–1.74) 1.32 (0.89–1.98) 1.13 (0.63–2.05) 0.83 (0.57–1.19)
Hazard ratios with 95% conﬁdence intervals indicating the risk of all-cause or mode-speciﬁc death in people with atrial ﬁbrillation. HF indicates heart failure.
*P<0.05; †age, sex, furosemide dose, implantable cardioverter-deﬁbrillator, warfarin, and digoxin; ‡age, sex, ischemic pathogenesis, hemoglobin, and estimated glomerular ﬁltration rate;
§age, sex, and resting heart rate (HR).
Figure 2. Age-sex–adjusted all-cause and mode-speciﬁc mortality in subgroups with ischemic and
nonischemic heart failure (HF). Forest plot demonstrating hazard ratios (with 95% conﬁdence intervals) for
all-cause and mode-speciﬁc mortality in patients with ischemic and nonischemic causes. CV indicates
cardiovascular. *Statistically signiﬁcant interaction between pathogenesis and atrial ﬁbrillation (AF;
indicating conﬁdence intervals are different with P<0.05).
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AF and HF of Ischemic Pathogenesis
In 2006, Pedersen et al9 reported that AF was only associated
with increased all-cause mortality in patients with a history of
IHD. However, only 50% of these patients were prescribed
an angiotensin-converting enzyme inhibitor, as patients were
recruited in 1993–1995, predating the introduction of stan-
dard therapies including b-blockers, mineralocorticoid recep-
tor antagonists, and complex devices. Raunsø et al8 also
observed in a cohort of patients with mixed HFrEF and HFpEF
recruited between 2001 and 2004 that chronic AF was
associated with increased risk of death in the subgroup with
IHD. These data are affected by similar limitations. Our data
substantially expand these observations by showing relevance
in the context of contemporary HFrEF therapies and providing
detailed mode-speciﬁc outcome data, including for cardiac
remodeling. Although the observational nature of our study
prevents a thorough assessment of the mechanisms under-
pinning our ﬁndings, our data suggest that AF may aggravate
the HF syndrome to a greater extent in people with ischemic
HF. Speciﬁcally, we noted greater loop diuretic dose and use
of mineralocorticoid receptor antagonists in patients with
ischemic HF and AF, along with higher rates of progressive HF
death. Notably, the age-sex–adjusted interaction between AF
and ischemic pathogenesis in all-cause mortality analyses was
lost (P=0.06) when further adjusting for diuretic dose,
implying differences in diuretic dose to explain at least a
proportion of the interaction. There are also animal data
demonstrating that AF can increase oxidative stress,
Table 3. Baseline Patient Characteristics According to HF Pathogenesis
Nonischemic Subgroup Ischemic Subgroup
No AF (n=189) AF (n=100) P Value No AF (n=379) AF (n=123) P Value
Age, y 59.6 (1.0) 67.4 (1.2) <0.001 70 (0.5) 74.4 (0.8) <0.001
Men 64 (121) 72 (72) 0.17 76.5 (290) 81.3 (100) 0.27
Diabetes mellitus 13.8 (26) 17 (17) 0.46 31.7 (120) 33.3 (41) 0.73
COPD 9.5 (18) 8 (8) 0.67 15.8 (60) 18.7 (23) 0.46
PPM/ICD/CRT 29.6 (56) 18 (18) 0.031 35.1 (133) 37.4 (46) 0.64
ICD 8.5 (16) 2 (2) 0.03 17.9 (68) 8.1 (10) 0.009
CRT 25.9 (49) 15 (15) 0.033 24.5 (93) 31.7 (39) 0.12
NYHA class 3/4 25.9 (49) 29 (29) 0.58 34.7 (131) 47.2 (58) 0.014
Warfarin 19.7 (37) 67 (67) <0.001 18.0 (68) 59.0 (72) <0.001
ACEI/ARB 91.5 (172) 84 (84) 0.054 88.1 (332) 86.9 (106) 0.73
b-Blocker 79.8 (150) 83 (83) 0.51 79.8 (301) 73.0 (89) 0.11
MRA 36.2 (68) 38 (38) 0.76 39.8 (150) 50.8 (62) 0.032
Digoxin 14.8 (28) 53 (53) <0.001 11.9 (45) 37.4 (46) <0.001
Amiodarone 7.9 (15) 10 (10) 0.55 10.8 (41) 5.7 (7) 0.093
Systolic BP, mm Hg 121.0 (1.6) 118.6 (2.1) 0.38 122.9 (1.2) 119.2 (1.8) 0.079
Resting HR on 12-lead ECG, bpm 77.0 (1.5) 84.5 (2.2) 0.004 70.0 (0.9) 73.5 (1.8) 0.082
QRS interval, ms 123.6 (2.5) 111.0 (3.4) 0.003 122.6 (1.6) 126.7 (2.9) 0.21
Hemoglobin, g/dL 13.9 (0.1) 14.3 (0.2) 0.091 13.3 (0.1) 13.5 (0.2) 0.23
Sodium, mmol/L 139.8 (0.2) 139.7 (0.3) 0.92 139.0 (0.2) 139.3 (0.3) 0.5
eGFR, mL/min per 1.73 m2 61.6 (1.3) 58.1 (1.6) 0.093 52.9 (0.9) 48.5 (1.5) 0.013
LVEF, % 29.3 (0.7) 32.5 (0.9) 0.01 33.4 (0.4) 32.2 (0.8) 0.16
Minimum ambulatory HR, bpm 58.6 (0.9) 62.7 (1.5) 0.019 55.5 (0.5) 56.6 (1.2) 0.38
Maximum ambulatory HR, bpm 111.2 (1.4) 131.1 (2.8) <0.001 98.3 (0.9) 109.0 (1.9) <0.001
Ramipril equivalent dose, mg/d 5.0 (0.2) 4.5 (0.4) 0.19 5.1 (0.2) 4.8 (0.3) 0.54
Bisoprolol equivalent dose, mg/d 3.1 (0.2) 4.3 (0.4) 0.005 3.6 (0.2) 3.3 (0.3) 0.39
Furosemide equivalent dose, mg/d 46.9 (3.7) 44.2 (4.3) 0.65 52.3 (2.7) 72.1 (4.7) <0.001
ACEI indicates angiotensin-converting enzyme inhibitor; AF, atrial ﬁbrillation; ARB, angiotensin receptor blocker; BP, blood pressure; bpm, beats per minute; COPD, chronic obstructive
pulmonary disease; CRT, cardiac resynchronization therapy; eGFR, estimated glomerular ﬁltration rate; HF, heart failure; HR, heart rate; ICD, implantable cardioverter-deﬁbrillator; LVEF, left
ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association; PPM, permanent pacemaker.
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ventricular ischemia, and endothelial dysfunction,19 while AF
decreases myocardial blood ﬂow in humans.20 One could
speculate that these pathophysiological effects may be more
important in patients with AF and HF due to IHD, although we
have no data as an objective measure of myocardial ischemia
in our cohort. It will be important for future studies to explore
these observations and those made by our study.
Study Limitations
It is important to acknowledge some limitations of our study.
First, observational studies cannot causally implicate AF, but
even randomized controlled trials of AF therapies cannot fully
address this question, as they are not uniformly effective and
suffer from crossover. Notably, prospective cohort studies
may also allow assessment of less selected populations than
post hoc analyses of randomized controlled trials. Second,
the manner in which we systematically determined the
presence of AF is a potential limitation, as this is not
necessarily practical in real-world care. It is also important to
acknowledge that longer periods of monitoring may have
identiﬁed more cases of AF. However, this factor is not one
limited to our study, and lack of interval monitoring of heart
rhythm is a common limitation in much of the literature that
investigates the prognostic impact of AF in patients with HF.
Indeed, the majority of published studies classify AF based
on medical history or a 12-lead ECG alone. Finally, the
relatively low proportion of pAF means that we do not have
the statistical power to assess the prognosis of this
important subgroup.
Conclusions
Our study suggests that AF is associated with increased risk
of all-cause and cardiovascular death, but only in patients with
HFrEF caused by IHD, and this risk only manifests during
longer-term follow-up. These data suggest that future trials of
interventional AF therapies should focus on patients with
ischemic HF and ensure long-term follow-up.
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